Panbela Therapeutics (PBLA) Competitors $0.36 +0.04 (+12.59%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends PBLA vs. EDSA, EYEN, GTBP, EVOK, ADIL, RNAZ, IMCC, VRAX, VCNX, and AIMDShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Edesa Biotech (EDSA), Eyenovia (EYEN), GT Biopharma (GTBP), Evoke Pharma (EVOK), Adial Pharmaceuticals (ADIL), TransCode Therapeutics (RNAZ), IM Cannabis (IMCC), Virax Biolabs Group (VRAX), Vaccinex (VCNX), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Edesa Biotech Eyenovia GT Biopharma Evoke Pharma Adial Pharmaceuticals TransCode Therapeutics IM Cannabis Virax Biolabs Group Vaccinex Ainos Edesa Biotech (NASDAQ:EDSA) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do insiders & institutionals believe in EDSA or PBLA? 5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor EDSA or PBLA? Edesa Biotech received 9 more outperform votes than Panbela Therapeutics when rated by MarketBeat users. Likewise, 77.14% of users gave Edesa Biotech an outperform vote while only 62.07% of users gave Panbela Therapeutics an outperform vote. CompanyUnderperformOutperformEdesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Panbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% Do analysts prefer EDSA or PBLA? Edesa Biotech currently has a consensus price target of $21.00, indicating a potential upside of 895.26%. Panbela Therapeutics has a consensus price target of $500.00, indicating a potential upside of 139,721.03%. Given Panbela Therapeutics' higher probable upside, analysts clearly believe Panbela Therapeutics is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, EDSA or PBLA? Edesa Biotech has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Which has higher valuation & earnings, EDSA or PBLA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$8.37MN/AN/APanbela TherapeuticsN/AN/A-$25.26M-$71.13-0.01 Is EDSA or PBLA more profitable? Panbela Therapeutics' return on equity of 0.00% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -137.95% -97.48% Panbela Therapeutics N/A N/A -302.61% Does the media prefer EDSA or PBLA? In the previous week, Panbela Therapeutics had 3 more articles in the media than Edesa Biotech. MarketBeat recorded 4 mentions for Panbela Therapeutics and 1 mentions for Edesa Biotech. Panbela Therapeutics' average media sentiment score of 0.41 beat Edesa Biotech's score of 0.00 indicating that Panbela Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Panbela Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryEdesa Biotech beats Panbela Therapeutics on 7 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.73M$6.57B$5.14B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio-0.019.56125.0517.04Price / SalesN/A364.791,232.2287.12Price / CashN/A52.5939.9936.27Price / Book-0.1010.176.956.36Net Income-$25.26M$153.36M$119.41M$226.00M7 Day Performance18.80%-1.63%-1.40%-0.02%1 Month Performance6.62%-7.17%-3.31%1.95%1 Year Performance-96.47%31.66%32.45%27.80% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela Therapeutics1.1143 of 5 stars$0.36+12.6%$500.00+139,721.0%-97.0%$1.73MN/A-0.017News CoverageGap UpEDSAEdesa Biotech3.1614 of 5 stars$2.11-4.1%$21.00+895.3%-27.9%$6.86MN/A0.0020Gap DownEYENEyenovia2.8402 of 5 stars$0.11+10.5%$2.00+1,802.9%-93.2%$6.73MN/A-0.1440Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeGTBPGT BiopharmaN/A$3.01-5.6%N/A-54.2%$6.71MN/A0.008EVOKEvoke Pharma0.0516 of 5 stars$4.50-1.3%N/A-69.5%$6.71M$5.18M-0.414Analyst ForecastADILAdial Pharmaceuticals2.5229 of 5 stars$1.02flat$8.00+684.3%-50.5%$6.54MN/A0.0020RNAZTransCode Therapeutics2.6543 of 5 stars$0.37+12.0%$3.00+704.1%-96.3%$6.44MN/A0.009IMCCIM Cannabis0.725 of 5 stars$2.81+1.4%N/A+12.6%$6.27M$36.15M-0.82340VRAXVirax Biolabs Group0.2726 of 5 stars$1.94+3.2%N/A-24.8%$6.27M$160,000.000.005VCNXVaccinex0.5996 of 5 stars$3.59-3.2%N/A-70.2%$6.21M$570,000.00-0.0740AIMDAinos0.681 of 5 stars$0.44+2.3%N/A-86.2%$6.16M$120,000.000.0046Gap Down Related Companies and Tools Related Companies Edesa Biotech Competitors Eyenovia Competitors GT Biopharma Competitors Evoke Pharma Competitors Adial Pharmaceuticals Competitors TransCode Therapeutics Competitors IM Cannabis Competitors Virax Biolabs Group Competitors Vaccinex Competitors Ainos Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBLA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
